Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,316 across all filing types
Latest filing 2025-07-25 Capital/Financing Update
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details a fund infusion by Dr. Reddy's Laboratories Limited into its step-down wholly-owned subsidiary in Russia, including investment amount, percentage stake acquired, and related party transaction information. The document is an announcement of a capital investment transaction and not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather provides regulatory disclosure about a financing event. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory disclosure about capital infusion.
2025-07-25 English
FORM 6-K
Regulatory Filings
2025-07-25 English
FORM 6-K
Regulatory Filings
2025-07-25 English
FORM 6-K
Regulatory Filings
2025-07-24 English
FORM 6-K
Regulatory Filings
2025-07-24 English
Appointment of Secretarial Auditor
Board/Management Information Classification · 95% confidence The document is a formal disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It announces the appointment of a new Secretarial Auditor approved by shareholders at the 41st AGM. The content is an announcement of a board/management related change, specifically the appointment of an auditor, and includes details required by SEBI regulations. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The document is short (3260 characters) and is an official announcement of a management-related change. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-07-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.